Profound Medical (NASDAQ:PROF) vs. INVO Bioscience (NASDAQ:INVO) Head-To-Head Analysis

Profound Medical (NASDAQ:PROF) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Insider & Institutional Ownership

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are held by institutional investors. 1.5% of Profound Medical shares are held by company insiders. Comparatively, 3.5% of INVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Profound Medical has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Earnings & Valuation

This table compares Profound Medical and INVO Bioscience”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$10.68 million	19.55	-$28.57 million	($1.12)	-6.21
INVO Bioscience	$5.77 million	0.14	-$8.03 million	N/A	N/A

INVO Bioscience has lower revenue, but higher earnings than Profound Medical.

Analyst Ratings

This is a breakdown of recent ratings for Profound Medical and INVO Bioscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	0	0	2	1	3.33
INVO Bioscience	0	0	0	0	0.00

Profound Medical presently has a consensus price target of $14.25, suggesting a potential upside of 105.04%. Given Profound Medical’s stronger consensus rating and higher possible upside, research analysts clearly believe Profound Medical is more favorable than INVO Bioscience.

Profitability

This table compares Profound Medical and INVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-349.41%	-85.22%	-64.87%
INVO Bioscience	-122.79%	N/A	-36.94%

Summary

Profound Medical beats INVO Bioscience on 7 of the 13 factors compared between the two stocks.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

About INVO Bioscience

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.